On vydamax tafamidas for wild type cardio
July 26
That's a really specific question, and unfortunately there isn't publicly available data on the percentage of people with wild-type amyloidosis who are receiving both Vyndamax (tafamidis) and Amvuttra (vutrisiran) together.
What is known is that both medications are approved for wild-type ATTR amyloidosis:
- Vyndamax Show Full Answer
That's a really specific question, and unfortunately there isn't publicly available data on the percentage of people with wild-type amyloidosis who are receiving both Vyndamax (tafamidis) and Amvuttra (vutrisiran) together.
What is known is that both medications are approved for wild-type ATTR amyloidosis:
- Vyndamax (tafamidis) is a TTR stabilizer that helps keep the transthyretin protein in its correct shape to prevent amyloid buildup in the heart
- Amvuttra (vutrisiran) is a gene silencer that reduces production of the transthyretin protein in the liver — it received approval for ATTR cardiomyopathy in March 2025
Since Amvuttra's approval for this use is very recent, combination therapy data is still quite limited. Whether combining these two treatments is beneficial, safe, or even commonly practiced is something specialists are still exploring.
The best step would be to speak with an amyloidosis specialist or cardiologist about whether a combination approach might make sense for a specific situation, as treatment decisions are very much made on a case-by-case basis.
July 26
Join
Your Privacy Choices
